We determined the possible associated determinants and analyzed whether gp96-associated antigenic peptides can be found in renal cell carcinoma (RCC). The gp96-peptide complexes were chromatographically purified from resected tumor tissue of RCC patients. SDS-PAGE and Western blot analysis confirmed gp96 using the gp96 monoclonal antibody, and its concentration was measured using BCA. Approximately 20 to 50 μg gp96-peptide complexes was obtained from 1 g RCC tissue. The mass spectrometry (MS) analysis of the eluted peptides included the initial profiling using matrix-assisted laser desorption/ionization time-offlight MS. Quadrupole time-of-flight MS combined with the Mascot search engine was used to identify the peptides and find proteins from primary sequence databases. MS analysis results demonstrated that the mass range of peptide associated with gp96 was from 1046.48 to 3501.56 Da. Further research confirmed the sequences of two gp96-associated peptides,
Introduction
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults and accounts for approximately 3% of all solid tumors. RCC is usually initially treated with radical or partial nephrectomy as the primary curative treatment. The conventional adjuvant therapy has limited contribution in improving postoperation survival rate because of the high resistance to chemotherapy and radiation therapy (1) . RCC is recognized as an immunogenic tumor based on its responsiveness to immunotherapy, incidence of spontaneous regression, and presence of lymphocytic infiltrates in tumor (2, 3) . Immunotherapy is an appealing approach to facilitate specific, anti-tumor activity with minimal toxicity. Heat shock protein-based cancer vaccine is the focus of studies on immunotherapy. Gp96 derived from human tumors can present antigenic peptides to CD8 + T cells and activate them both in vitro and in vivo (4) . Immunization with autologous gp96 preparations isolated from cancer cells can elicit a cancer-specific protective T cell immune response that is recallable, which is a prerequisite for gp96 as a therapeutic vaccine against cancers. The gp96 functions as a molecular chaperone and can associate with a variety of antigenic peptides noncovalently (5, 6) . The collection of gp96-associated peptides represents the antigenic peptide pool of a cell. The repertoire of antigenic peptides in the cell is different between normal and tumor cells and is also distinct among tumors of the same histology because of the randomness of tumor-specific mutations. Hence, a purified sample of gp96-peptide complexes is designed to accommodate the unique genetic mutations underlying each patient's cancer (7) . This novel personalized cancer vaccine has made remarkable progress in recent years, but the major challenges include the limited origination of tissue and the complicated purification procedures, which make it difficult for commercial production (8) . The antigenicity is derived not from gp96 but from gp96-associated peptides (9) . Peptide motifs of endogenous peptides complexed with the different stress proteins have not yet been published. The identification of appropriate tumor antigens is perhaps the greatest challenge in cancer immunotherapy (10) . Therefore, we attempted to analyze and identify gp96-asssociated peptides, which can provide significant information in the development of effective cancer vaccine. We extracted and purified gp96-peptide complexes from RCC tissue, then analyzed the amino acid sequence of peptides isolated from gp96 by MS. This work can provide rationale in the development of peptide vaccine and assembly of gp96-peptide complexes in vitro.
Materials and Methods
Monoclonal Abs to gp96 (anti-Grp94, SPA-850, and clone 9G10) was obtained from StressGen Biotechnologies Corp. (Victoria, British Columbia, Canada).
Human RCC Tissue Samples
Eligible patients had primary-intact renal tumor and were scheduled to undergo nephrectomy at the Second Affiliated Hospital of Tianjin Medical University, TianJin, China. All patients have pathologically confirmed RCC with resectability of at least one lesion that was able to provide the necessary amount of tissue. Macroscopically non-necrotic tumor tissue was obtained under sterile conditions from the operating room, weighed, snap-frozen in liquid nitrogen, and subsequently stored at 280°C and used for gp96 purification. This study was conducted with the approval from the institutional bioethics committee and with the informed consent from all patients and the relatives of healthy donors.
GP96 Purification
Gp96 was purified from RCC tumor tissues with slight modifications as described earlier by Srivastava (11) . Tumor tissues were homogenized using a Dounce homogenizer in 40 mL hypotonic buffer (30 mM NaHCO 3 , pH 7.0) containing 1 mM phenylmethylsulfonyl fluoride (Sigma, USA). The homogenate was clarified by centrifugation at 20,000 3 g for 20 min. The supernatant was centrifuged at 100,000 3 g for 1 h. The resulting supernatants were then subjected to successive 50 and 80% ammonium sulfate precipitations by the gradual addition of the appropriate amount of ammonium sulfate at 4°C under constant gentle agitation and stored at 4°C for at least 4 h. The solution was centrifuged at 6000 rpm for 20 min. The pellet from this step was dissolved carefully in PBS (5 mM sodium phosphate, 2 mM MgCl 2 , 2 mM CaCl 2 , 160 mM NaCl, pH 7.4). The solution was filtered through a 5 μm filter, applied on a ConA-Sepharose (Pharmacia, Sweden) previously equilibrated with PBS, washed with 10 column-volume of the same buffer or until the absorbance at 280 nm dropped to near zero and was stable. We empirically repeated the load thrice, and then incubated at 37°C for 20 min. Then, the glycoproteins were eluted with 10% methyl-α-d-mannose pyranoside (Sigma, USA). The collected fractions were then applied to PD-10 columns (Pharmacia, Sweden) equilibrated with 10 mM sodium phosphate buffer (pH 7.0), containing 300 mM NaCl. After the buffer exchange, the samples were loaded on to a DEAE-Sepharose (Pharmacia, Sweden) column equilibrated with 10 mM sodium phosphate buffer (pH 7.0), containing 300 mM NaCl, and the bound gp96 was eluted in seven separate fractions with 10 mM sodium phosphate buffer (pH 7.0), containing 700 mM NaCl. The eluted proteins were determined on SDS-PAGE and immunoblot. The identity of the gp96 was confirmed by immunoblot using anti-gp96/grp94 monoclonal antibody, quantified by a BCA protein quantification assay (Pierce, USA) according to the manufacturer's instructions using bovine serum albumin as a standard. Fractions containing a single gp96 band on silverstained gels were used in subsequent experiments.
Isolation of Peptide from GP96
The gp96 sample prepared using this procedure was first concentrated using a Millipore 10 kDa Ultrafree membrane filter to 2 mg/mL, and then buffer-exchanged by a PD-10 gel filtration column with PBS containing 150 mM NaCl to remove any species non-specifically bound to gp96. Guanidine hydrochloride was added directly into the sample to a final concentration of 6 M. Stock solution of 1% trifluoroacetic acid (TFA) was then added into the sample to a final TFA concentration of 0.2%. This sample solution was set at 37°C for 30 min to strip the peptides from gp96. After incubation, the sample was cooled to room temperature and passed through a Millipore 10 kDa Ultrafree filter. The filtrate was injected onto a Zorbax StableBond C18 reversed phase HPLC column (5 μm, 4.6 mm 3 250 mm, Agilent Technologies) using multiple 1 mL injections. A 10 min wash step using 0.1% TFA in water was included between injections to wash the high concentration of salts, thus minimizing their impact on the subsequent injections. After the sample was completely injected, the column was further washed with 0.1% TFA in water for 30 min to ensure the complete removal of salts. The peptides that were enriched on the column were eluted with an acetonitrile gradient of 0 to 20% from 0 to 20 min and 20 to 70% from 20 to 40 min. All buffers contained 0.1% TFA (12) . The flow rate was 1 mL/min and detection was set at 214 nm. The eluent was collected in 1 min fractions and dried using a SpeedVac system (Eppendorf concentrator 5301). The dry fractions were redissolved in 15 μL of 5% acetonitrile containing 0.1% TFA.
MS Analysis of GP96-associated Peptides
The analysis of reconstituted fractions by MS includes the initial peptide profiling using matrix-assisted laser desorption ionization-time-of-flight MS (MALDI-TOF MS, Reflex III, Bruker Daltonics, Germany), and the subsequent peptide identification used quadrupole time-of-flight MS equipped with an electrospray ionization (ESI) source (LC-ESI-MS/MS, Q-TOF2, Micromass, UK) combined with protein database search using the Mascot (www.matrix-science.com) database searching software from Matrix Sciences (London, UK).
Peptide Mass Fingerprinting by MALDI-TOF MS
Each HPLC fraction was analyzed for the masses of peptides by MALDI-TOF MS using a saturated solution of 4-hydroxyα-cyanocinnamic acid in 50% acetonitirile and 0.1% TFA as matrix. Typically, 1 μL of the reconstituted sample was mixed with 4 μL of the matrix solution, and 1 μL of the mixture was spotted onto an AnchorChip TM sample plate provided by the manufacturer. All the HPLC fractions were prepared similarly and spotted onto the sample plate. The peptide calibration standard (Bruker) was prepared using the matrix solution, and 1 μL of the solution was spotted onto the sample plate to serve as an external calibrant. The sample plate was set at room temperature to dry and crystallize, and then placed into the instrument for MS analysis. The instrument was set to the following conditions: an acceleration voltage of 20 kV with a 130 ns delay; mirror voltage is 23 kV; detection voltage is 1.6 kV; and a mass range of 500 to 5000 Da. The data were analyzed using the Data Explorer software provided with the instrument. Most of the ions were observed between 1000 m/z and 3500 m/z, which represent the peptides with molecular masses between 1000 and 3500 Da.
Peptide Sequencing by Tandem ESI-MS
MS experiments were performed using a Q-TOF 2 tandem mass spectrometer equipped with an ESI interface in positive-ion mode and a disposable palladium-coated borosilicate electrospray needle (Protana, Odense, Denmark) to identify the eluted peptide from gp96. The instrument was switched to nano-ESI mode with a source temperature of 80°C and a potential of 800 to 1000 V applied to the nanospray probe. The selected ion was fragmented in the collision cell with argon gas. The instrument operating parameters were optimized as follows: orifice voltage, 50 V; TOF accelerating voltage, 9.1 kV; and MCP detection voltage, 2.2 kV. For each peptide, when the intensity exceeded the set point of the main peak, the MS/MS detection was conducted automatically. Accurate mass measurements of each peak from the total ion chromatograms were obtained using an automated calibrant delivery system with a dual-nebulizer ESI source. All mass spectra were acquired in the positive-ion mode. The accurate mass data of the precursor, specific product ion mass/charge ratios (m/z), and peak area of the extracted ion chromatogram signal were processed using the MassLynx V4.1 Data Analysis software from the manufacturer.
Results and Discussions
Comprehensive experimental evidence on the association of gp96 with peptides was recently found to be essential for cross-presentation and activation of T cells. Consequently, gp96-peptide complexes extracted from cancer cells harbor tumor-specific peptides and are immunogenic, offering a tool for active immunization against the tumor (13) (14) (15) (16) (17) . Therefore, immunologists speculate that every preparation of gp96associated peptide pool is different. Meanwhile, antigenic peptides derived from viral, tumor, and minor histocompatibile antigens have been isolated from gp96 and identified. These important studies have collectively identified antigenic peptide from cells/tissues that were infected by the peptide directly or indirectly with a specific epitope. The subsequent identification may be relatively easy because the concentration of peptide is presumably high after infection. An H-2K bbinding immunodominant viral peptide (SIINFEKL) was identified from OVA-transfected cell line E.G7 (18) , and an HBV-specific peptide (YVNTNMG) was identified from HBV-positive HCC tissue (19) . However, the characteristics of peptides associated with the RCC-derived gp96 remains ambiguous.
The properties of gp96 to chaperone antigenic fingerprint of a specific cancer, as well as the potent and protective immunogenicity generated by immunization with such complexes, have been utilized as an individually therapeutic vaccine in several Phase I/II clinical trials in various malignancies (20) (21) (22) (23) (24) . In principle, the clinical trials performed at present have indicated the safety and feasibility of this personalized gp96-based vaccine approach. In addition, two controlled and randomized Phase III clinical trials, one each in stage IV melanoma (25) and adjuvant RCC (26, 27) , have been completed recently. In the RCC trial, no difference was found in the recurrence-free survival between the Vitepsen (the trade marker of gp96-peptide complexes) and observation groups. However, these trials have shown a statistically significant benefit to the vaccination of patients with minimal or stable residual disease. In addition, a recent study has demonstrated a general mechanism to elicit individual patient-specific immune responses and appeared to correlate with the clinical outcome showing that immune responders have a median survival of 47 wk compared with 16 wk for the non-responder (28) . The adjuvant treatment of RCC was approved by the Russian Ministry of Health (29) . In addition, the adjuvant treatment of RCC has received fast track and orphan drug designations from the U.S. FDA for the treatment of MM, RCC, and glioma. RCC is an ideal tumor model for immunological interventions because the primary burden is often large and the initial treatment includes radical nephrectomy, allowing easy purification of gp96. However, the analysis of human RCC tissue to evaluate the identity of associated peptide(s) has not yet been previously reported and is therefore a worthy endeavor. In the present study, we attempted to seek the possible associated determinants and analyzed the occurrence of gp96-associated antigenic peptides in an RCC tumor model. The tumor specimen was homogenized and centrifuged, and the resulting supernatant was precipitated using ammonium persulfate. The resulting precipitate was then passed through sequential chromatography columns, and the fractions containing gp96 were verified in SDS-PAGE analysis (Figures  1 and 2) . Approximately 20 to 50 μg of gp96-peptide complexes was obtained from 1 g RCC tissue, consistent with the results in other studies (11, 30) . Gp96 is a family of highly conserved proteins present in the cells of all organisms and functions as molecular chaperone, which assists the correct folding of polypeptides and aids the intracellular protein transport. In addition, gp96 is associated with a broad range of peptides derived from intracellular protein degradation. Consequently, the gp96-peptide complexes extracted from cancer cells harbor tumor-specific peptides and are immunogenic (14, 31, 32) . Various methods for stripping and separating the peptides from other HSP molecules have also been reported (18, 19, 33) . Although specific procedure may work for certain HSP molecules, the procedure reported in the present study should be applicable for the gp96 molecule. Low-molecular mass material bound to gp96 molecules was isolated by acid treatment, followed by filtration over centricon filters and a final separation on C18 reverse phase HPLC. Then, the reconstitution buffer that consists of 5% acetonitrile containing 0.1% TFA was chosen to increase peptide recovery and facilitate subsequent analysis by MS, which prefers the use of organic solvent and volatile buffers (12) .
The Q-TOF 2 MS results representing the mass range of peptides associated with gp96 are from 1046.48 to 3501.56 Da (Figure 3 ). An array of peptides was observed from each of the eight fractions, which suggested the diversity of peptides associated with gp96. Two peptides with molecular masses of 1270.6843 and 1370.0743 were analyzed through quadrupole collision. The corresponding sequences of the two gp96associated peptides were LVPLEGWGGNVM ( Figure 4 ) and PPVYYVPYVVL ( Figure 5 ). Linderoth et al. (34) demonstrated the binding of recombinant gp96 with peptide in stable multimeric complexes using scanning transmission electron microscopy. Site-directed mutagenesis was used to understand the biological significance of specific aromatic amino acid residues in the gp96 peptide-binding pocket. The eluted peptides are possibly hydrophobic or hydrophilic, with indifferent lengths (12, 34) . The gp96-associated peptides is essential for cross-presentation and activation of T cells (14, 32) . The carboxyl terminal of the peptide presented by the MHC I molecules was commonly aliphatic hydrophobic amino acid (I, L, V, M). In the present experiment, we deduced two peptides composed of 11 and 12 amino acids with carboxyl terminals L and M, respectively. The above results show that the peptides eluted from RCC tissue-derived gp96 are in accordance with the features of the MHC I-binding and gp96-associated peptides. The molecular mass of these fragments and their relative intensities were converted into a simple text file and imported into the Mascot database search engine to search the Swiss-Prot protein database for a possible protein candidate that matches the fragmentation pattern of the spectrum. The search did not generate a confident hit. The theoretical recovery of the peptide cannot be calculated because the number of gp96 molecules in a complete cell is unknown. We obtained 500 μg (approximately 5200 pmol) from 10 g tissue using the aforementioned methods. Earlier reports have shown a peptide recovery of approximately 0.1% using a similar method. This finding influenced the subsequent MS analysis results. Peptides identified using the protocols described earlier were only associated with gp96 in the solution. However, the specificity and relevance of this association to the immunogenicity of gp96 remains to be elucidated. Nevertheless, the identification of more peptides from gp96 will increase our understanding of HSP/peptide interaction and shed light on the nature and origin of these peptide antigens.
